Übersicht der Publikationen

Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies

Moritz Thran, Marion Pönisch, Hillary Danz, Nigel Horscroft, Konstantin Ichtchenko, Saul Tzipori & Charles B. Shoemaker,
Scientific Reports, September 2023

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

Makda S. Gebre, Susanne Rauch, Nicole Roth, Jingyou Y u , A bi shek Chandrashekar, Noe B. Mercado, Xuan He, Jinyan Liu, Katherine McMahan, Amanda Martinot, David R. Martinez, Tori Giffin, David Hope, Shivani Patel, Daniel Sellers, Owen Sanborn, Julia Barrett, Xiaowen Liu, Andrew C. Cole, Laurent Pessaint, Daniel Valentin, Zack Flinchbaugh, Jake Yalley-Ogunro, Jeanne Muench, Renita Brown, Anthony Cook, Elyse Teow, Hanne Andersen, Mark G. Lewis, Adrianus C. M. Boon, Ralph S. Baric, Stefan O. Mueller, Benjamin Petsch & Dan H. Barouch, Nature, November 2021.

Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model

Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo, MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD, Journal of Hepatology, August 2021.

mRNA-Based Vaccines and Mode of Action

Gergen J, Petsch B, Current Topics in Microbiology and Immunology, February 2021.

mRNA: A novel Avenue to Antibody Therapy

Schlake et al.; Molecular Therapy, April 2019

New Vaccine Technologies to Combat Outbreak Situations

Rauch et al., Front. Immunol., September 2018.

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

Heinzerling et al., presented at the 2018 Society for Immunotherapy of Cancer Annual Meeting, November 2018.

mRNA as novel technology for passive immunotherapy

Schlake et al., Cellular and Molecular Life Sciences, June 2018.

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

Thran et al., EMBO Molecular Medicine, August 2017.

Immunological effects of a novel RNA-based adjuvant in liver cancer patients

Circelli et al., Cancer Immunology Immunotherapy, November 2016.

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

Rausch S et al, Human Vaccines & Immunotherapeutics, Jan. 2015.

The regulatory landscape for actively personalized cancer immunotherapies

Cedrik M Britten et al, Nature Biotechnology, Oct. 2013.

A novel, disruptive vaccination technology, Self-adjuvanted RNActive® vaccines

Kallen K-J et al, Human Vaccines & Immunotherapeutics, Oct. 2013.

Developing mRNA-vaccine technologies

Schlake T et al., RNA Biology, Oct. 2012.

mRNA: delivering an antitumor message

Van Lint S et al., Immunotherapy, May 2011.

Characterization of the ribonuclease activity on the skin surface

Probst J et al., Genetic Vaccines and Therapy, May 2006.

Vaccination with messenger RNA

Pascolo S, Methods in Molecular Medicine, Review 2006.

RNA-based Therapies

Pascolo S, Drug Discovery Handbook, by Shayne Cox Gad, July 2005.

Co-transfection of messenger RNA and siRNA as a method to study the efficiency of siRNA

Mutzke T et al., Nucleosides Nucleotides and Nucleic Acids, 2005.

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines

Carralot JP et al., Cellular and Molecular Life Sciences, Sept. 2004.

Messenger RNA-based vaccines

Pascolo S, Expert Opinion on Biological Therapy, Aug. 2004.

Immunostimulating capacities of stabilized RNA molecules

Scheel B et al., European Journal of Immunology, Feb. 2004.